SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma reports 36% rise in Q3 net profit

28 Jan 2015 Evaluate

Ajanta Pharma has reported results for third quarter ended December 31, 2014.

The company has registered a rise of 35.71% in its net profit at Rs 84.71 crore for the quarter under review as compared to Rs 62.42 crore for the same quarter in the previous year. Total income of the company has increased 20.98 % at Rs 368.84 crore for Q3FY15 as compared Rs 304.88 crore for the corresponding quarter previous year.

Ajanta Pharma is engaged in manufacturing pharmaceutical products. The company runs three divisions -- prescription drugs, OTC and institutional sales.

Ajanta Pharma Share Price

3102.10 8.85 (0.29%)
07-May-2026 12:45 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1842.50
Dr. Reddys Lab 1310.35
Cipla 1373.30
Zydus Lifesciences 941.40
Lupin 2465.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×